Nvidia founder Jensen Huang has previously highlighted three core areas for AI application implementation: large language models, embodied AI, and AI for Science. Since the beginning of the year, the AI application sector in the Hong Kong stock market has continued to gain momentum, becoming a focal point for capital markets. While the market debates who leads this space, XTALPI, focused on AI pharmaceuticals and AI for Science, has provided an answer with its actual performance. Dubbed the "first stock under Chapter 18C," this tech company has delivered what can be described as a "phenomenal" report card amidst skepticism: revenue growth surged by 193%, losses narrowed significantly, and it became the first AI application company in Hong Kong to achieve profitability. This performance evokes the industry pattern mentioned in "Shenzhen's Prophecy: Who Will Be the Next Trillion-Dollar Tencent" – during the internet era, Tencent stood out by achieving profitability first and eventually grew into an industry giant. Today, in the race for AI applications, XTALPI appears to be rising along a similar path.
This profitability achievement is no accident. A deeper analysis of XTALPI's financial data and business layout reveals that its profitability is supported by comprehensive capabilities, which also fuels imagination about its future growth potential. The hallmarks of a leader in Hong Kong's AI application sector are gradually becoming evident.
1. Strong and Accelerating Growth Momentum with a Solid Foundation. XTALPI has exceeded performance expectations for two consecutive years, with growth showing an accelerating trend, demonstrating the robustness of its core business. Its operations in small molecules, antibodies, bispecific antibodies, peptides, mRNA drug研发, and robotic automation are flourishing. More notably, the company's technological completeness is rare on a global scale, establishing a strong technical barrier for long-term growth.
2. Moving Beyond Reliance on Single Orders, Highlighting Growth Resilience. The market previously focused on the second payment for a large order from last year. However, even without including this revenue, the company still achieved high growth,充分证明ing its growth is not dependent on a single project. Combined with the company's consistently prudent management style, the second payment should be assured, potentially representing an unreleased positive catalyst.
3. Remarkable Reduction in Losses with a Clear Path to Profitability. From a loss of 1.9 billion in 2023 to a loss of 1.65 billion in 2024, and then directly eliminating the loss to achieve profitability in 2025 – such a significant narrowing of losses is rare in the Hong Kong stock market. It fully reflects management's excellent strategy and efficient execution in operational optimization. Compared to some AI companies struggling with high computing costs, XTALPI has successfully validated a sustainable, high-impact business model for AI applications in pharmaceuticals and materials, which is the core reason for its率先 profitability.
4. Smooth Progress in Collaboration Pipelines with Huge Commercial Potential. Pipelines being advanced with multiple partners have now entered clinical stages, showing excellent data performance. The realization of future milestone payments is expected to bring explosive growth in net profit for XTALPI.
5. Robotic Automation Builds Core Barriers, Creating Differentiated Competitive Advantages. The robotic automation business is becoming a key growth driver. In the AI field, pure algorithm companies may struggle to compete against giants like OpenAI and Google, which possess data and capital advantages. Leveraging China's complete hardware supply chain and cost advantages, XTALPI is building dual barriers in hardware and data generation through automated laboratories. These labs are not only efficient production tools but also engines generating proprietary data continuously, forming a竞争优势 that is difficult to replicate.
6. Forward-Looking Expansion into Consumer Goods with Significant Potential. XTALPI has innovatively applied its drug研发 platform to the consumer goods sector. This segment features short cycles and fast returns, perfectly aligning with Asia's vast population base and complementing its drug研发 efforts. The hair growth market it is targeting holds immense potential, with user feedback indicating significant effectiveness for its products. This segment has the potential to become a major cash cow for XTALPI in the future.
7. Gradual Realization of Incubation Ecosystem Value. XTALPI's unique incubation ecosystem is poised to yield substantial returns. As an important shareholder, XTALPI stands to gain considerable exit profits, further boosting company earnings.
8. Strong Cash Reserves Enable Potential M&A Expansion. Over the past year, XTALPI has utilized the flexibility of the Hong Kong capital market to accumulate substantial cash reserves and establish good market liquidity. With a "stock issuance + cash" model, XTALPI possesses strong merger and acquisition integration capabilities. Compared to peers, its robust cash position is a unique advantage, positioning it for leapfrog growth through future M&A activities and further business expansion.
9. Policy Support and New Growth Space in AI for Materials. Repeated visits by national leaders underscore strong government support for the industrialization of AI applications. XTALPI has also been securing increasing cooperation in the AI for materials field. Given China's massive industrial scale and data availability in chemicals, photovoltaics, and energy, this market segment holds boundless potential.
Breaking through skepticism and leading the industry wave, XTALPI's rise is no coincidence. With a complete technological system, robust operational capabilities, forward-looking business布局, and substantial financial reserves, this company focused on AI pharmaceuticals and AI for Science is beginning to demonstrate the qualities of a leader in Hong Kong's AI application sector. On the fast track of accelerating AI application implementation, XTALPI undoubtedly represents a highly scarce, high-growth target in the Hong Kong market, and its future potential warrants continued market anticipation.
Comments